Publication:
Cucurbitacin B inhibits human breast cancer cell proliferation through disruption of microtubule polymerization and nucleophosmin/B23 translocation

dc.contributor.authorSuwit Duangmanoen_US
dc.contributor.authorPhorntip Sae-limen_US
dc.contributor.authorApichart Suksamrarnen_US
dc.contributor.authorFrederick E Domannen_US
dc.contributor.authorPimpicha Patmasiriwaten_US
dc.contributor.otherMahidol University. Faculty of Medical Technologyen_US
dc.date.accessioned2017-08-23T08:18:02Z
dc.date.available2017-08-23T08:18:02Z
dc.date.created2017-08-23
dc.date.issued2012
dc.description.abstractBackground: Cucurbitacin B, an oxygenated tetracyclic triterpenoid compound extracted from the Thai medicinal plant Trichosanthes cucumerina L., has been reported to have several biological activities including anti-inflammatory, antimicrobial and anticancer. Cucurbitacin B is great of interest because of its biological activity. This agent inhibits growth of various types of human cancer cells lines. Methods: In this study, we explored the novel molecular response of cucurbitacin B in human breast cancer cells, MCF-7 and MDA-MB-231. The growth inhibitory effect of cucurbitacin B on breast cancer cells was assessed by MTT assay. The effects of cucurbitacin B on microtubules morphological structure and tubulin polymerization were analyzed using immunofluorescence technique and tubulin polymerization assay kit, respectively. Proteomic analysis was used to identify the target-specific proteins that involved in cucurbitacin B treatment. Some of the differentially expressed genes and protein products were validated by real-time RT-PCR and western blot analysis. Cell cycle distributions and apoptosis were investigated using flow cytometry. Results: Cucurbitacin B exhibited strong antiproliferative effects against breast cancer cells in a dose-dependent manner. We show that cucurbitacin B prominently alters the cytoskeletal network of breast cancer cells, inducing rapid morphologic changes and improper polymerization of the microtubule network. Moreover, the results of 2D-PAGE, real-time RT-PCR, and western blot analysis revealed that the expression of nucleophosmin/B23 and c-Myc decreased markedly after cucurbitacin B treatment. Immunofluorescence microscopy showed that cucurbitacin B induced translocation of nucleophosmin/B23 from the nucleolus to nucleoplasm. Treatment with cucurbitacin B resulted in cell cycle arrest at G2/M phase and the enhancement of apoptosis. Conclusions: Our findings suggest that cucurbitacin B may inhibit the proliferation of human breast cancer cells through disruption of the microtubule network and down-regulation of c-Myc and nucleophosmin/B23 as well as the perturbation in nucleophosmin/B23 trafficking from the nucleolus to nucleoplasm, resulting in G2/M arrest.en_US
dc.identifier.citationBMC Complementary and Alternative Medicine. Vol.12, (2012), 185en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/2768
dc.language.isoengen_US
dc.rightsMahidol Universityen_US
dc.rights.holderBioMed Centralen_US
dc.subjectCucurbitacin Ben_US
dc.subjectNucleophosmin/B23en_US
dc.subjectTubulinen_US
dc.subjectBreast canceren_US
dc.subjectOpen Access articleen_US
dc.titleCucurbitacin B inhibits human breast cancer cell proliferation through disruption of microtubule polymerization and nucleophosmin/B23 translocationen_US
dc.typeArticleen_US
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
mt-ar-pimpicha-2012.pdf
Size:
1.64 MB
Format:
Adobe Portable Document Format

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:

Collections